GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (STU:19X) » Definitions » Research & Development

Axsome Therapeutics (STU:19X) Research & Development : €173.6 Mil (TTM As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Axsome Therapeutics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Axsome Therapeutics's Research & Development for the three months ended in Dec. 2024 was €52.5 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was €173.6 Mil.

Axsome Therapeutics Research & Development Historical Data

The historical data trend for Axsome Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics Research & Development Chart

Axsome Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.74 51.38 54.70 89.82 178.66

Axsome Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.25 33.88 46.31 40.90 52.53

Axsome Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €173.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axsome Therapeutics  (STU:19X) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Axsome Therapeutics Research & Development Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Axsome Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (STU:19X) » Definitions » Research & Development
Comparable Companies
ADMA NUVL KRYS CYTK BPMC IONS SRPT PCVX LEGN RYTM VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
AXSM:USA 0HKF:UK 19X:Germany
Address
One World Trade Center, 22nd Floor, New York, NY, USA, 10007
Website
https://www.axsome.com
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Axsome Therapeutics Headlines

No Headlines